lundi 20 février 2017

Onco Actu du 20 février 2017

2. Etiologie

Radiotherapy for invasive breast cancer increases risk of lung cancer [ecancernews]

3.1.1 Tabac - e-cigs

Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems (ENDS): An Information-Gathering Workshop [National Academies]

Lawmakers seek to help e-cigarette makers escape new regulations [STAT]

3.6 Prévention - Activité physique

Report: Clinicians Should Routinely Counsel Patients on Physical Activity [ACS]

4.12 Biopsies liquides

New blood test could detect early-stage pancreatic cancer [Stanford Medicine]

4.13 Dép., diag. & prono. - Peau

Is That A Brown Recluse Spider Bite Or Skin Cancer? [NPR]

4.2 Dép., diag. & prono. - Génome

Genome analysis helps keep deadly brain cancer at bay for five years [Yale Cancer Center]

4.9 Dép., diag. & prono. - Sein

Mammograms At The Shopping Mall Raise Interesting Questions About How We Get Our Health Care [Dr. Len]

5.10 Traitements - Essais

Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma [Roche]

ArQule’s lead drug tivantinib flops again in PhIII liver cancer study [EndPoints]

5.12.2 Immunothérapies - CAR-T

Despite deaths and trial halts, Leerink sees Juno positives [FierceBiotech]

5.12.5 Immunothérapies - Pharma

Prima Biomed starts new trials of lead I-O drug but needs more cash, say analysts [FierceBiotech]

5.2 Pharma

Myriad's BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, Olaparib [Myriad]

Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer [AstraZeneca]

AstraZeneca throws down the gauntlet with a PhIII victory in head-to-head PARP war with Tesaro [EndPoints]

5.2.1 Pharma - Partenariats

New collaboration with Pfizer aimed at speeding drug discovery [WUSTL]

5.5 ASCO

Myriad's Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer [Myriad]

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors [Exelixis]

Four New Studies of Oncotype DX® Genomic Prostate Score™ (GPS) Reconfirm Value of Test in Guiding Early-stage Prostate Cancer Risk Assessment and Treatment Selection [Genomic Health]

Bayer to Showcase Xofigo® Prostate Cancer Data at ASCO GU 2017 [Bayer]

6. Lutte contre les cancers

Alarming number of cancer medics suffering burnout and stress [The Guardian]

6.10 Politiques

Cancer charity welcomes NHS u-turn on second stem cell treatments [The Guardian]

France should do more to help scientists become entrepreneurs, report says [Science]

6.10.1 Politiques (USA)

The show goes on: Trump attends controversial Dana-Farber fundraiser at Mar-a-Lago [STAT]

Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers [NCI]

6.11 Patients

In Maintenance Mode, Living in the Moment [NY Times]

6.5 Médecines alternatives

Homeopathy for breast cancer surgery? Isn’t it bad enough that the patient has cancer and needs a mastectomy? [Respectful Insolence]

Texas board recommends sanctions against controversial cancer doctor [STAT]

6.6 Publications

What's So Special About Signing In? [ORCID]

Publication should not be the endgame of medical research [BMJ Blogs]

Cancer biologist stops research as his retraction count rises to 13 [Retraction Watch]

6.7 DMP, Big Data & applis

MD Anderson Benches IBM Watson In Setback For Artificial Intelligence In Medicine [Forbes]

Touted IBM supercomputer project at MD Anderson on hold after audit finds spending issues [Houston Chronicle]